EGFR testing was also less likely among patients with any Medicaid or no/unknown insurance compared to those with private/military/other insurance (OR range: 0.15–0.20), among patients with large cell tumors compared to those with adenocarcinomas (OR: 0.04; 95% CI: 0.01–0.23), among patients who had comorbidities (OR: 0.33; 95% CI: 0.16–0.68) and patients who died within two months of their cancer diagnosis (OR: 0.24; 95% CI: 0.08–0.73). The gene discussed is EGFR; the disease is adenocarcinoma.